The latest biotech news

boehringer ingelheim cancer vaccine amal therapeutics

News and Trends 10 Apr 2020

Coronavirus Pandemic Bites into European Cancer Research

The UK funder Cancer Research UK and Swedish oncology biotech Alligator Bioscience have independently announced cuts to payroll and research costs due to the coronavirus disease pandemic. Cancer Research UK is cutting research funding by €50M after calculating it will lose a quarter or more of its annual fundraising income — or €137m — through […]

April 10, 2020 - 4 minutesmins - By Anita Chakraverty

epigenetics review cambridge epigenetix oryzon1

News and Trends 9 Apr 2020

Two European Alzheimer’s Disease Treatments Show Promise in Phase II

An epigenetics drug developed by the Spanish biopharmaceutical company Oryzon has reduced aggressive behavior in patients with Alzheimer’s disease and improved the experience of their caregivers in a phase IIa trial. At the same time, an Alzheimer’s vaccine developed by the Austrian biotech Axon Neuroscience has lowered a key blood biomarker of neurodegeneration by almost […]

April 9, 2020 - 4 minutesmins - By David Kirk

Altheia Science gene therapy autoimmune disease

News and Trends 8 Apr 2020

Evotec Makes Move into Gene Therapy with Takeda Deal

German biotech giant Evotec has moved into gene therapy and partnered with Takeda to develop new therapies in oncology, rare diseases, neuroscience, and gastroenterology. The two companies did not reveal financial details of the collaboration, but did say that it will be a multi-year alliance that adds to Evotec’s existing deal with the big pharma […]

April 8, 2020 - 3 minutesmins - By Helen Albert

News and Trends 6 Apr 2020

UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients

The UK company Izana Bioscience is freely providing its phase III-ready anti-inflammatory antibody namilumab in a compassionate use program for the treatment of patients with coronavirus disease in Italy. In severe cases of coronavirus disease, also known as Covid-19, patients experience hyperinflammation. One of the drivers of inflammation is thought to be a protein called […]

April 6, 2020 - 2 minutesmins - By David Kirk

News and Trends 3 Apr 2020

UK-US Initiative to Screen Drugs Using AI for Coronavirus Treatments

The UK company Exscientia will use its AI-driven drug discovery platform to examine a collection of 15,000 potential coronavirus disease treatments in collaboration with the US research institute Calibr and the non-profit synchrotron company Diamond Light Source. The team’s huge collection of drug molecules will be provided by Calibr, part of the US medical institute […]

April 3, 2020 - 4 minutesmins - By David Kirk

News and Trends 3 Apr 2020

Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M

Eli Lilly will partner Oxford-based Sitryx to develop up to four drug candidates to treat autoimmune disease in a deal worth €811M if development milestones are met. The UK biotech will receive an upfront payment of €46M from the US big pharma, which will also buy €10M of equity in the company. Sitryx can also […]

April 3, 2020 - 2 minutesmins - By Helen Albert

News and Trends 2 Apr 2020

iTeos Therapeutics’ Cancer Immunotherapy Boosted with €114M Funding

An oversubscribed Series B2 round has seen the biopharmaceutical company iTeos Therapeutics raise €114M, which will be used to advance the clinical development of its two lead cancer immunotherapies. The funds follow on from €65M raised by iTeos in Series B financing in 2018. Since then, the Belgian company has completed a phase I trial […]

April 2, 2020 - 3 minutesmins - By Laura Cowen

novartis avexis zolgensma fda data manipulation

News and Trends 2 Apr 2020

Update: FDA Imposes No Penalties for Novartis Data Manipulation Scandal

Update (02/04/2020): The FDA has concluded an investigation into a data manipulation scandal surrounding the approval of Novartis’ gene therapy Zolgensma, and has decided against sanctions. The FDA launched an investigation into the manipulated data surrounding the gene therapy application last year, and recently reported that the investigated data violations didn’t meet the threshold for […]

April 2, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 2 Apr 2020

Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment

The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease, also known as Covid-19. The therapeutic mRNA would be delivered directly into the lungs of symptomatic patients via nebulizers with nanoparticle aerosols. The mRNA could […]

April 2, 2020 - 3 minutesmins - By Anita Chakraverty

News and Trends 31 Mar 2020

Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial

The French pharmaceutical company Ipsen has restarted the dosing of its treatment for a rare bone disease in a phase III trial after obtaining questionable interim results. At the same time, the company has terminated a phase II trial of the same drug in pediatric patients with a different bone disorder following a partial clinical […]

March 31, 2020 - 4 minutesmins - By Karen O’Hanlon Cohrt

News and Trends 31 Mar 2020

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant

The Japanese heavyweight Ono Pharmaceutical has recruited Numab Therapeutics for a second time to co-develop a multi-specific antibody cancer treatment in a deal worth up to €246M (CHF 260M). The announcement follows a two-year collaboration between Ono and Numab announced in March 2017. Under the new agreement, which includes upfront and milestone payments, Ono has […]

March 31, 2020 - 3 minutesmins - By David Kirk

News and Trends 31 Mar 2020

Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M

Update (31/03/2020): AM-Pharma has raised an extra €47M on top of an existing €116M equity round to fund an upcoming phase III trial of a treatment for acute kidney injury. The money will help the Dutch biotech to prepare for its upcoming phase III trial of a protein drug for acute kidney injury, which is […]

March 31, 2020 - 3 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Coronavirus Pandemic Bites into European Cancer Research

Two European Alzheimer’s Disease Treatments Show Promise in Phase II

Evotec Makes Move into Gene Therapy with Takeda Deal

UK Biotech’s Arthritis Drug Enters Study in Coronavirus Patients

UK-US Initiative to Screen Drugs Using AI for Coronavirus Treatments

Lilly Partners UK Immunometabolism Biotech in Deal Worth €811M

iTeos Therapeutics’ Cancer Immunotherapy Boosted with €114M Funding

Update: FDA Imposes No Penalties for Novartis Data Manipulation Scandal

Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment

Ipsen Resumes Phase III Testing for Rare Disease Drug and Abandons Pediatric Trial

Swiss Biopharma Launches Second Cancer Antibody Deal with Japanese Pharma Giant

Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!